[
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  }
]